Developing new therapies to combat tuberculosis through inhibition of vitamin B5 metabolism in the organism that causes the disease

通过抑制引起疾病的生物体中的维生素 B5 代谢来开发抗击结核病的新疗法

• 批准号: nhmrc : GNT1016357
• 负责人: Dr Christina Spry
• 金额: $ 20.79万
• 依托单位: Australian National University
• 依托单位国家: 澳大利亚
• 项目类别: Early Career Fellowships
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/developing-new-therapies-causes-disease/1344275
• 关键词: Developing; new; therapies; combat; tuberculosis

The metabolism of vitamin B5 by pathogenic microorganisms has been recognised as an attractive target for developing drugs to combat various infectious diseases. The aim of the proposed work is to develop inhibitors of vitamin B5 metabolism in the bacterium that causes tuberculosis, using a powerful, multidisciplinary approach known as “fragment-based drug discovery”. This work is likely to yield potent inhibitors of the target bacterium, which could ultimately be used to treat tuberculosis.

病原微生物对维生素B5的代谢已被认为是开发抗击各种传染病的药物的一个有吸引力的靶点。这项拟议工作的目的是利用一种被称为“基于片段的药物发现”的强大的多学科方法，开发引起结核病的细菌中维生素B5代谢的抑制剂。这项工作很可能产生目标细菌的有效抑制剂，最终可能用于治疗结核病。